Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2010
06/03/2010US20100135960 Antiviral acylsulfonamide derivatives
06/03/2010US20100135958 Method for treating cancer in humans
06/03/2010US20100135956 Steroid modulators of progesterone receptor and/or glucocorticoid receptor
06/03/2010US20100135954 6-Phenylpyrimidinones as PIM Modulators
06/03/2010US20100135952 Methods for the treatment of renal failure
06/03/2010US20100135950 Iron(II)-Containing Treatments for Hyperphosphatemia
06/03/2010US20100135948 Anti-Autoimmune Antibodies for Treatment of Pemphigus
06/03/2010US20100135936 Delivery of hydrophobic benefit agents from bodywashes and the like onto a keratinous substrate
06/03/2010US20100135935 Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications
06/03/2010US20100135904 Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling
06/03/2010US20100135903 Use of a dna damaging agent and a ligand for the treatment of cancer
06/03/2010US20100135900 Cd37 immunotherapeutic combination therapies and uses thereof
06/03/2010CA2777638A1 Genetic variants useful for risk assessment of thyroid cancer
06/03/2010CA2748344A1 Enhanced bioactive formulations of resveratrol
06/03/2010CA2746205A1 Dosage form for insertion into the mouth
06/03/2010CA2745046A1 Moisturizing mixture, cosmetic and/or pharmaceutical compositions containing the moisturizing mixture, use of the moisturizing mixture, and cosmetic method
06/03/2010CA2745012A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
06/03/2010CA2745005A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
06/03/2010CA2745004A1 Pyridine-3-carboxyamide derivative
06/03/2010CA2744996A1 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
06/03/2010CA2744990A1 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
06/03/2010CA2744937A1 Hsp90 inhibitor combinations
06/03/2010CA2744892A1 Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof
06/03/2010CA2744861A1 Controlled release pharmaceutical compositions comprising o-desmethyl-venlafaxine
06/03/2010CA2744857A1 Cyclobutyl purine derivative, angiogenesis promoting agent, lumen formation promoting agent, neurocyte growth promoting agent, and drug
06/03/2010CA2744833A1 Benzonaphtyridine compounds as inhibitors of autotaxin
06/03/2010CA2744828A1 Five crystal forms, methods of preparation, pharmaceutical compositions and applications of 3-(3'-carboxy-4'-hydroxy-anilino-carbo-)-6-nitro-7-hydroxy-8-methyl-coumarin)>>
06/03/2010CA2744819A1 A new family of pain producing substances and methods to produce novel analgesic drugs
06/03/2010CA2744817A1 Bile acid recycling inhibitors for treatment of obesity and diabetes
06/03/2010CA2744705A1 Compositions and methods for treating hoof diseases
06/03/2010CA2744694A1 Rna interference mediated inhibition of epithelial sodium channel (enac) gene expression using short interfering nucleic acid (sina)
06/03/2010CA2744655A1 Novel powdered crystalline medicines for inhalation
06/03/2010CA2744515A1 Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin-ii antagonist and/or a diuretic
06/03/2010CA2744513A1 Difluorophenyldiacylhydrazide derivatives
06/03/2010CA2744505A1 Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
06/03/2010CA2744458A1 Novel processes and pure polymorphs
06/03/2010CA2744449A1 Methods for the treatment of infections and tumors
06/03/2010CA2744448A1 Polymorphs
06/03/2010CA2744369A1 2-(n-substituted piperazinyl) steroid derivatives
06/03/2010CA2744360A1 Hybrid -ionone and curcumin molecules as anticancer agents
06/03/2010CA2744355A1 Compositions and methods for treating retrovirus infections
06/03/2010CA2744309A1 Rocaglaol derivatives as cardioprotectant agents and as antineoplastic agents
06/03/2010CA2744178A1 Indole derivatives, method for preparing same and pharmaceutical compositions containing same
06/03/2010CA2744141A1 Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics
06/03/2010CA2744138A1 Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
06/03/2010CA2744021A1 Nitrooxy cycloalkane derivatives
06/03/2010CA2743976A1 Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
06/03/2010CA2743887A1 Transdermally administered aliskiren
06/03/2010CA2743722A1 Hsp90 inhibitors for therapeutic treatment
06/03/2010CA2743427A1 Antioxidant compositions for soft oral tissue and methods of formulation and use thereof
06/03/2010CA2743241A1 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
06/03/2010CA2743097A1 Regioselective reduction of fused pyrrolocarbazoles -5,7-diones
06/03/2010CA2743030A1 3-aminocyclopentanecarboxamides as chemokine receptor modulators
06/03/2010CA2743018A1 Substituted pyrazole compounds
06/03/2010CA2742645A1 Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
06/03/2010CA2742539A1 Disubstituted phthalazine hedgehog pathway antagonists
06/03/2010CA2742463A1 3-(benzylamin0)-pyrr0lidine derivatives and their use as nk-3 receptor antagonists
06/03/2010CA2742350A1 Novel substituted octahydrocyclopenta(c)pyrrol-4-amines as calcium channel blockers
06/03/2010CA2741928A1 Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
06/03/2010CA2741760A1 Pyrazolylaminopyridines as inhibitors of fak
06/03/2010CA2741751A1 Extended release oral acetaminophen/tramadol dosage form
06/03/2010CA2741746A1 Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
06/03/2010CA2741731A1 Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
06/03/2010CA2741303A1 Substituted pyrazoloquinolines and derivatives thereof
06/03/2010CA2740975A1 Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
06/03/2010CA2740900A1 Antibodies that specifically block the biological activity of a tumor antigen
06/03/2010CA2740865A1 Mouthwash in the form of a stable suspension comprising microspheres that incorporate an active ingredient
06/03/2010CA2739251A1 Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
06/02/2010EP2192191A1 Method for production of carotenoid
06/02/2010EP2192190A1 Yogurt containing pectin hydrolysis products
06/02/2010EP2192183A1 Triterpene oxidase derived from plant belonging to genus glychyrrhiza, gene encoding the triterpene oxidase, and use of the protein or the gene
06/02/2010EP2192179A1 Cdh3 peptide and medicinal agent comprising the same
06/02/2010EP2192122A1 Dithiolopyrrolone compounds, the preparation and the use thereof
06/02/2010EP2192120A1 Stable crystalline salt of 5-methyll-(6S)-tetrahydrofolic acid
06/02/2010EP2192116A1 Indazole acrylic acid amide compound
06/02/2010EP2192114A1 bis [O-(14-benzoylaconine-8-yl)] esters
06/02/2010EP2192113A1 Novel crystal form XI of atorvastatin hemi-calcium and processes for its preparation
06/02/2010EP2192112A1 Process for preparing atorvastatin hemi-calcium Form I
06/02/2010EP2192109A1 Bicyclic -amino acid derivative
06/02/2010EP2192108A1 Novel dihydronaphthalene compound and use thereof
06/02/2010EP2191899A1 Phosphatase inhibitor sample collection system
06/02/2010EP2191890A1 Process for producing fine particles and the fine particles
06/02/2010EP2191849A1 Drug for suppressing pathogen occurring<i>in vivo</i>
06/02/2010EP2191848A1 Sustained release preparation and process for production thereof
06/02/2010EP2191846A1 Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
06/02/2010EP2191845A1 Immunology significant herpes simplex virus antigens and methods for using same
06/02/2010EP2191843A1 Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
06/02/2010EP2191842A1 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
06/02/2010EP2191841A1 Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
06/02/2010EP2191840A1 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
06/02/2010EP2191834A1 Compositions and methods for treating retrovirus infections
06/02/2010EP2191833A1 Transdermally absorbable preparation
06/02/2010EP2191832A1 Quinazoline derivatives which promote the release of parathyroid hormone
06/02/2010EP2191831A1 Modifying pirfenidone treatment for patients with atypical liver function
06/02/2010EP2191830A1 Solid preparation comprising npyy5 receptor antagonist
06/02/2010EP2191829A2 Treatment of endocrine dysfunction using iron chelators
06/02/2010EP2191828A1 Antifungal pharmaceutical composition
06/02/2010EP2191827A1 Antifungal composition
06/02/2010EP2191826A1 Pharmaceutical composition
06/02/2010EP2191825A1 Agent for fungal dermatitis
1 ... 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 ... 7860